Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal female subjects, aged between 18 and 37 years inclusive~* Subjects willing to conceive~* Subjects who are infertile due to chronic anovulation demonstrated by a cycle duration of \> 35 days, or regular cycles with progesterone (P4) levels \< 1 nanomole/milliliter (nmol/mL) during luteal phase (Day 25)~* Subjects who have experienced spontaneous menses, menses induced by clomiphene citrate therapy, or a positive progestin-induced withdrawal within the previous year~* Subjects with FSH and PRL serum values within the normal range in the early follicular phase~* Subjects with total antral follicle count (AFC) \> 10 (of follicle size ≥ 2 mm and \< 11 mm) in both ovaries~* Subjects with at least 1 patent tube, as documented by recent (within 2 years before treatment assignment) hysterosalpingography (HSG)~* Subjects with normal uterine cavity, as documented by recent (within 2 years before treatment assignment) hysteroscopy, HSG or ultrasound scan~* Subjects with body mass index (BMI) \>20 and ≤32 kilogram square per meter (kg/m\^2)~* Subjects with negative cervical Papanicolaou (PAP) test within the 6 months prior to screening~* Male partners of female subjects with sperm compatible with non assisted fertilization~* Subjects who are willing and able to participate in the study and have provided written, informed consent~Exclusion Criteria:~* Subjects with history of hypersensitivity to the active substance follitropin alpha, FSH, or to any of the excipients of Gonal-f~* Subjects with ovarian enlargement or ovarian cyst unrelated to PCOS, and of unknown origin on ultrasound~* Subjects with evidence of diminished ovarian reserve (cycle length \< 26 days; FSH above the upper limit of local serum FSH values, total AFC in both ovaries \< 10)~* Subjects with myomatous uterus, which in the opinion of the investigator could impair pregnancy evolution~* Subjects who have undergone 3 or more previous miscarriages~* Subjects with any previous extrauterine pregnancy~* Pregnant or lactating female subjects~* Subjects with abnormal gynecological bleeding of unknown etiology~* Subjects with previous history of severe OHSS~* Subjects who have undergone operative pelvic surgery which could induce mechanical infertility (e.g tubes blockage) or pelvic inflammatory disease (PID) before treatment assignment excluding curettage and hysteroscopy~* Subjects with tumors of the hypothalamus and pituitary gland~* Subjects with ovarian, uterine or mammary carcinoma~* Subjects treated with clomiphene citrate or gonadotropins within 1 month of the screening evaluation~* Subjects with any medical condition which, in the opinion of the investigator, would prevent an effective response, such as primary ovarian failure, or malformations of the reproductive organs incompatible with pregnancy~* Subjects with any medical condition which, in the opinion of the investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug~* Subjects with any clinically significant systemic disease (e.g. insulin-dependent diabetes) or any contraindication to being pregnant and/or carrying a pregnancy to term; also including subjects with non insulin dependent diabetes mellitus (NIDDM)~* An active substance abuser~* Subjects with known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus in the trial subject or her male partner~* Subjects who have simultaneously participated in another clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Group I: Chronic Low dose Protocol (Type: EXPERIMENTAL): Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
- Group II: Low dose Protocol (Type: EXPERIMENTAL): Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete